At Roche we focus on developing medicines and diagnostics that will help patients live longer, better lives. We strive to address unmet medical needs through excellence in science - from early detection and prevention of diseases to diagnosis, treatment and treatment monitoring. Roche's Pharma Research and Early Development organization - Roche pRED - consists of some 2,500 scientists and clinicians with a shared vision of excellence in science, a proud heritage of healthcare innovation and a commitment to deliver new and effective medicines to patients.

Roche contributed from the start to establishing and driving the Innovative Medicines Initiative (IMI) with the aim of making the drug-development process safer and more efficient. Besides its role in K4DD, Roche participates already in many other ongoing IMI projects. Generally for IMI projects, and specifically for K4DD, the goal is the development of new methodologies and techniques to enable the safety and efficacy of new drugs to be predicted more reliably in the future. At Roche, we observed in drug discovery projects that the dissociation rates of ligands were important for their efficacy and safety. K4DD is expected to deliver methods to improve efficacy and safety prediction by accounting also for effects of binding kinetics.